Literature DB >> 10458349

A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder.

J W Slaton1, D A Swanson, H B Grossman, C P Dinney.   

Abstract

PURPOSE: Surveillance protocols after radical surgery for genitourinary tumors typically do not consider that the risk of recurrence is stage dependent. We describe the development of a stage specific protocol for monitoring patients with transitional cell carcinoma for tumor recurrence and conduit complications after radical cystectomy.
MATERIALS AND METHODS: The records of 382 patients with transitional cell carcinoma who underwent cystectomy in 1986 to 1994 were reviewed for the dates and presenting symptoms of local and distant recurrences, and the results of radiological imaging studies and liver function tests. Based on the division of patients into pathological stages of pT1, pT2 and pT3 groups, we developed a new transitional cell carcinoma surveillance protocol.
RESULTS: Of 97 patients with transitional cell carcinoma metastases 72 (74%) were asymptomatic, including 43 with metastases detected by routine chest x-rays (30) or blood tests (13). Surveillance computerized tomography identified isolated asymptomatic intra-abdominal metastases in 10 patients (10%), of whom 90% had pT3 disease. Based on these results we recommend a stage specific surveillance protocol for pT1--annual history, physical examination, chest x-ray and laboratory studies, pT2-same studies at 6, 12, 18, 24, 30, 36, 48 and 60 months after cystectomy, and pT3-same studies at 3, 6, 12, 18, 24, 30, 36, 48 and 60 months plus computerized tomography at 6, 12 and 24 months after cystectomy. A radiographic study of the upper tract should be performed in all patients every 1 to 2 years to evaluate for recurrences and complications of the ileoureteral anastomosis.
CONCLUSIONS: A stage driven surveillance strategy for monitoring patients after radical cystectomy can reduce costly imaging studies while efficiently detecting recurrences and complications.

Entities:  

Mesh:

Year:  1999        PMID: 10458349     DOI: 10.1097/00005392-199909010-00021

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder.

Authors:  Ken-ichi Harada; Iori Sakai; Toshifumi Kurahashi; Mototsugu Muramaki; Kazuki Yamanaka; Isao Hara; Hiroshi Eto; Hideaki Miyake
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 2.  Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?

Authors:  S Machele Donat
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols.

Authors:  Nathan Perlis; Polat Turker; Peter J Bostrom; Cynthia Kuk; Tuomas Mirtti; Girish Kulkarni; Neil E Fleshner; Michael A S Jewett; Antonio Finelli; Alexandre R Zlotta
Journal:  World J Urol       Date:  2012-07-19       Impact factor: 4.226

4.  B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma.

Authors:  Min Fan; Qianfeng Zhuang; Yiming Chen; Tao Ding; Hongwei Yao; Lujun Chen; Xiaozhou He; Xianlin Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Squamous cell carcinoma in exstrophy of the bladder.

Authors:  Pramod Kumar Sharma; Praveen Kumar Pandey; Mukesh Kumar Vijay; Malay Kumar Bera; Jitendra Pratap Singh; Kaushik Saha
Journal:  Korean J Urol       Date:  2013-08-07

Review 6.  [Local recurrence following radical cystectomy for bladder cancer. Diagnostic and therapeutic options].

Authors:  J Simon; J E Gschwend; B G Volkmer
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

7.  Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.

Authors:  Behfar Ehdaie; Steven C Smith; Dan Theodorescu
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 8.  Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.

Authors:  Andrea B Apolo; Herbert Barton Grossman; Dean Bajorin; Gary Steinberg; Ashish M Kamat
Journal:  Urol Oncol       Date:  2012 Nov-Dec       Impact factor: 3.498

9.  A case of isolated rectal recurrence of muscle invasive bladder cancer.

Authors:  Shaqil N Kassam; Zared Aziz; Lick San Hung; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

Review 10.  Radical Cystectomy in Female Patients - Improving Outcomes.

Authors:  Nikolaos Kalampokis; Nikolaos Grivas; Markus Ölschläger; Fahmy Nabil Hassan; Georgios Gakis
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.